News
The SELECT trial demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its ...
2d
News-Medical.Net on MSNCan one drug do it all? Reviewing the expanding clinical universe of GLP-1 agonistsLandmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...
What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...
Ozempic and Zepbound are both prescription injections that are part of the GLP-1 drug class. They have different active ...
Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...
GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...
3d
Onlymyhealth on MSNOzempic Mouth: Understanding The Unwanted Side Effect Of The Weight-Loss MedicationIn recent times, medications like Ozempic (semaglutide) have gained popularity not only for managing type 2 diabetes but also ...
2d
Best Life on MSNThe #1 Side Effect That Makes the Most People Quit Ozempic and MounjaroWeight loss injections like Ozempic, Wegovy, and Mounjaro have revolutionized the obesity fight, helping millions of Americans shed stubborn pounds, lower their blood sugar, and reduce their risk of ...
Ozempic has always come with side effects. The latest? Thinning hair and muscle loss. Experts break down why this might be ...
4dOpinion
The Star on MSNDR NELLY: Kenya’s quiet shift in diabetes and obesity treatmentKenya’s healthcare system is witnessing a quiet transformation with the introduction of newer therapies for managing Type 2 ...
Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results